For Healthcare Professionals

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

clipboard-pencil

About the study

The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Male and female subjects
  2. Age ≥ 85 years

Age ≥ 65 and < 85 years with one or more of the following conditions:


  1. Asthma
  2. Chronic Obstructive Pulmonary Disease (COPD)
  3. Chronic bronchitis
  4. Type 2 Diabetes Mellitus (T2DM)
  5. Congestive Heart Failure (CHF) New York Heart Association (NYHA) functional classification I-II
  6. Current smoker
  7. One or more emergency room visits or hospitalizations for a RTI during the previous 12 months

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Subjects with medically significant cardiac conditions including NYHA functional classification III-IV
  2. Subjects with Type I diabetes mellitus.
  3. Subjects with clinically significant underlying pulmonary disease other than asthma, GOLD Class I and II COPD or chronic bronchitis

History of malignancy in any organ system within the past 5 years except for the following:


Localized basal cell or squamous cell carcinoma of the skin, prostate cancer confined to the gland, cervical carcinoma in situ, breast cancer localized to the breast.


Subjects with any one of the following:


  1. hemoglobin < 10.0 g/dL for males and < 9.0 for females
  2. white blood cell (WBC) count < 3,500/mm3,
  3. neutrophil count < 2,000/mm3
  4. platelet count < 125,000/mm3
  5. Subjects with a history of a systemic autoimmune disease or receiving immunosuppressive therapy
  6. Recent surgery other than minor skin surgery
  7. Liver disease or liver injury
  8. History or presence of impaired renal function
  9. History of immunodeficiency diseases
  10. Subjects with active infection
  11. Subjects with a Mini Mental Status Examination (MMSE) score <24 at screening.
  12. Significant illness (based on the subject's medical history and the clinical judgement of the investigator) which has not resolved within two (2) weeks prior to initial dosing.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Respiratory Tract Infections

Age (in years)

65+

Phase

Phase 2

Participants needed

652

Est. Completion Date

Jul 31, 2018

Treatment type

Interventional


Sponsor

Restorbio Inc.

ClinicalTrials.gov identifier

NCT03373903

Study number

RTB-BEZ235-202

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.